MedTrace Logo

Effect Of Semaglutide In Coronary Atheroma Plaque

NCT05071417 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2021-10-08

No results posted yet for this study

Summary

The main objective of this trial is to evaluate the effect of Semaglutide on the burden of coronary atherosclerosis, based on the change in Percent Atheroma Volume (PAV) by quantifying atheroma plaque throughout the coronary tree based on the analysis of CCTA in asymptomatic subjects with T2D in optimized and stable treatment with Semaglutide.

Conditions

  • Atheroscleroses, Coronary

Interventions

DRUG

Semaglutide

Usual treatment with semaglutide. Dose 0.5 - 1mg weekly, subcutaneous, weekly

Sponsors & Collaborators

  • Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León

    lead OTHER

Principal Investigators

  • Leopoldo Pérez de Isla · Hospital Clínico San Carlos. Madrid. Spain.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-30
Primary Completion
2024-12-31
Completion
2025-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05071417 on ClinicalTrials.gov